{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:39:35Z","timestamp":1769837975132,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730003, 81828001, 81972807 and 81970179"],"award-info":[{"award-number":["81730003, 81828001, 81972807 and 81970179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX09304021"],"award-info":[{"award-number":["2017ZX09304021"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SLT201911"],"award-info":[{"award-number":["SLT201911"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aim of the study was to delineate the disease characteristics, the initial treatment patterns, and survival in patients with mantle cell lymphoma (MCL) managed in the real world.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data of 518 MCL patients from 5 major Chinese Hematology Centers in the period from 2007 to 2017 were retrospectively analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 58\u00a0years. Of the patients, 88.6% had Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0\u20131 and 80.7% had advanced-stage disease. Ki67 expression was &amp;lt;30% in 39.6% of the patients, and 43.2% of patients were categorized into a low-risk group based on the Mantle Cell Lymphoma International Prognostic Index (MIPI) scoring system. Overall, 73.4% of the patients received rituximab as their first-line therapy. The most commonly used chemotherapy was the CHOP-like (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) regimen (45.2%), followed by high-dose cytarabine-containing chemotherapy (31.3%) and bendamustine (3.3%). Of the patients, 13.7% (<jats:italic>n<\/jats:italic>\u00a0=\u00a071) underwent consolidative autologous stem cell transplantation (ASCT), and 19.3% (<jats:italic>n<\/jats:italic>\u00a0=\u00a0100) received novel agents containing first-line regimens. With a median follow-up time of 52 months, the 3- and 5-year overall survival (OS) rates were 73.7% and 61.4%, respectively. Age \u226460\u00a0years, ECOG PS 0\u20131, stages I\u2013II, normal lactate dehydrogenase (LDH), absence of bone marrow involvement, Ki67 &amp;lt;30%, and lower-risk IPI\/MIPI scores were significantly associated with improved OS (<jats:italic>p<\/jats:italic>\u00a0&amp;lt;\u00a00.05). The inclusion of rituximab improved the 5-year OS, with borderline significance (62.5% <jats:italic>vs<\/jats:italic>. 55.2%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.076). High-dose cytarabine-containing chemotherapy showed significant clinical benefit in 5-year OS (72.1% <jats:italic>vs<\/jats:italic>. 55.9%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.010). Patients with ASCT had better 5-year OS in the younger (\u226460\u00a0years) age group (87.2% <jats:italic>vs<\/jats:italic>. 64.8%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This large retrospective dataset unequivocally confirmed the survival advantage afforded by cytarabine-containing regimen and ASCT in a first-line setting under real-world management in the rituximab era.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.770988","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T05:55:31Z","timestamp":1641275731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Meng","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909","article-title":"A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000447577","article-title":"Epidemiology of Non-Hodgkin's Lymphoma in India","volume":"91","author":"Nair","year":"2016","journal-title":"Oncology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of Lymphoid Neoplasms in China: Analysis of 4,638 Cases According to the World Health Organization Classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx333.","article-title":"Observation as the Initial Management Strategy in Patients With Mantle Cell Lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569.","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15170","article-title":"Impact of Novel Therapies for Mantle Cell Lymphoma in the Real World Setting: A Report From the UK UK 'S Haematological Malignancy Research Network ( HMRN HMRN )","volume":"181","author":"Smith","year":"2018","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real World Data on Primary Treatment for Mantle Cell Lymphoma: A Nordic Lymphoma Group Observational Study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487","article-title":"Mantle Cell Lymphoma: 2019 Update on the Diagnosis, Pathogenesis, Prognostication, and Management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128710","article-title":"The Addition of Rituximab to Fludarabine and Cyclophosphamide Chemotherapy Results in a Significant Improvement in Overall Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma: Results of a Randomized UK National Cancer Research Institute Trial","volume":"101","author":"Rule","year":"2016","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of Rituximab to Chemotherapy Alone as First-Line Therapy Improves Overall Survival in Elderly Patients With Mantle Cell Lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment for Patients With Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised, Phase 3 non-Inferiority Trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605","article-title":"First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab After Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial","volume":"38","author":"Kluin-Nelemans","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of High-Dose Cytarabine to Immunochemotherapy Before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger With Mantle Cell Lymphoma (MCL Younger): A Randomised, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-Term Progression-Free Survival of Mantle Cell Lymphoma After Intensive Front-Line Immunochemotherapy With In Vivo-Purged Stem Cell Rescue: A Nonrandomized Phase 2 Multicenter Study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 Trial Update: Six-Year Follow-Up After Intensive Immunochemotherapy for Untreated Mantle Cell Lymphoma Followed by BEAM or BEAC + Autologous Stem-Cell Support: Still Very Long Survival But Late Relapses do Occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241","article-title":"15-Year Follow-Up of the Second Nordic Mantle Cell Lymphoma Trial (MCL2): Prolonged Remissions Without Survival Plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab Plus HyperCVAD Alternating With High Dose Cytarabine and Methotrexate for the Initial Treatment of Patients With Mantle Cell Lymphoma, a Multicentre Trial From Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796","article-title":"Rituximab Plus Hyper-CVAD Alternating With MTX\/Ara-C in Patients With Newly Diagnosed Mantle Cell Lymphoma: 15-Year Follow-Up of a Phase II Study From the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early Consolidation by Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle-Cell Lymphoma: Results of a Prospective Randomized Trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00690","article-title":"Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.2009.2009","article-title":"The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)","volume":"130","author":"Sawalha","year":"2017","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-Year Follow-Up of Lenalidomide Plus Rituximab as Initial Treatment of Mantle Cell Lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide Plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326.","article-title":"Long-Term Follow-Up of MCL Patients Treated With Single-Agent Ibrutinib: Updated Safety and Efficacy Results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33108-2.","article-title":"Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (ACE-LY-004): A Single-Arm, Multicentre, Phase 2 Trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3703.","article-title":"Treatment of Patients With Relapsed or Refractory Mantle-Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.770988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T05:55:36Z","timestamp":1641275736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.770988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":31,"alternative-id":["10.3389\/fonc.2021.770988"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.770988","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"article-number":"770988"}}